Cite
HARVARD Citation
Mesa, R. et al. (2022). Momelotinib reduces transfusion requirements in patients with myelofibrosis. Leukemia & lymphoma. 63 (7), pp. 1718-1722. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Mesa, R. et al. (2022). Momelotinib reduces transfusion requirements in patients with myelofibrosis. Leukemia & lymphoma. 63 (7), pp. 1718-1722. [Online].